Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX) announced its quarterly earnings results on Thursday. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.12), FiscalAI reports. Syndax Pharmaceuticals had a negative net margin of 279.31% and a negative return on equity of 160.60%. The company had revenue of $68.73 million during the quarter. During the same quarter last year, the business earned ($1.10) EPS. Syndax Pharmaceuticals’s revenue for the quarter was up 792.6% on a year-over-year basis.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Syndax reported strong commercial momentum for Revuforj, with $124.8M net revenue in 2025, a 38% sequential increase in Q4, ~35% prescription growth, and rapid uptake following the NPM1 label expansion.
• The Niktimvo launch outperformed benchmarks—$151.6M partner-reported net sales in 2025 (Syndax recorded $42.4M collaboration revenue) and high persistency, supporting expectations for growing margin contribution over time.
• Pipeline execution is advancing—pivotal frontline trials for revumenib (EVOLVE-2, REVEAL-ND, RAVEN) are enrolling and axatilimab completed Phase 2 enrollment in IPF (MAXPIRe) with top-line data expected in Q4 2026, creating multiple potential near- and mid-term value drivers.
• Financial position and guidance are solid, with total 2025 revenue of $172.4M, $394M in cash and equivalents, and 2026 R&D+SG&A guidance of ~ $400M (ex‑noncash stock comp), and management expects to reach profitability without raising additional capital.
• Key commercial assumptions remain uncertain—average Revuforj treatment duration was only ~4–6 months in year one and revenue growth depends on extended durations, higher post‑transplant restart rates, and broader combination/frontline uptake that may not materialize as projected.

Syndax Pharmaceuticals Stock Down 0.4%

Shares of SNDX stock traded down $0.08 on Thursday, reaching $20.67. 1,358,353 shares of the company were exchanged, compared to its average volume of 1,129,768. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. The company has a 50-day moving average of $20.84 and a 200-day moving average of $17.93. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -5.73 and a beta of 0.46. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $22.73.

Analysts Set New Price Targets

Several research firms have weighed in on SNDX. Wall Street Zen upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. UBS Group raised their price objective on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Barclays lifted their target price on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. BTIG Research restated a “buy” rating and issued a $56.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.20.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,410 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the completion of the sale, the chief financial officer directly owned 140,429 shares of the company’s stock, valued at $2,953,221.87. This represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael A. Metzger sold 17,159 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $360,853.77. Following the sale, the chief executive officer directly owned 491,690 shares of the company’s stock, valued at $10,340,240.70. The trade was a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,063 shares of company stock worth $628,332. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its stake in shares of Syndax Pharmaceuticals by 2,698.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock worth $55,000 after acquiring an additional 2,564 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after purchasing an additional 1,922 shares during the last quarter. Quantbot Technologies LP purchased a new position in Syndax Pharmaceuticals in the 3rd quarter worth $53,000. Lazard Asset Management LLC bought a new stake in Syndax Pharmaceuticals in the second quarter worth $66,000. Finally, Tower Research Capital LLC TRC boosted its position in Syndax Pharmaceuticals by 103.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after buying an additional 4,308 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.